Can Genius Be Engineered? The Ethics and Science of Cognitive Enhancement
Every strand of research this series has examined — genetics, neuroplasticity, working memory, deliberate practice, mentorship, environment — converges on a single practical question that has moved from speculative fiction to active scientific and ethical debate over the past two decades: if we increasingly understand the biological, psychological, and environmental ingredients of exceptional cognitive achievement, can any of them be deliberately engineered, accelerated, or artificially enhanced, and if so, should they be? This closing pair of articles turns from describing the science of genius as it naturally occurs toward examining the emerging science, and the accompanying ethical controversy, of deliberately manufacturing it.
Pharmacological Enhancement: What Actually Works, Modestly
The most immediately available and most widely used form of cognitive enhancement involves pharmacological intervention, primarily using stimulant medications originally developed to treat attention-deficit/hyperactivity disorder, most notably methylphenidate (marketed as Ritalin) and various amphetamine-based medications (marketed as Adderall). Their use by people without an ADHD diagnosis specifically to enhance cognitive performance — sometimes called “cognitive doping” in the academic literature — has become widespread, particularly among university students, with survey research finding non-prescribed stimulant use rates at some competitive universities reported as high as 20-30% in certain self-report surveys, though estimates vary considerably across studies and populations.
The actual research evidence on these substances’ cognitive effects in non-ADHD individuals is more modest and more complicated than their popular reputation as straightforward “smart drugs” suggests. A comprehensive and widely cited 2015 meta-analysis led by Irena Ilieva reviewed the accumulated experimental literature and found that stimulant medications in healthy, non-ADHD individuals produced small but measurable improvements in some aspects of executive function, particularly inhibitory control, and modest improvements in memory consolidation tasks — but found no reliable evidence of improvement in fluid reasoning or genuinely novel problem-solving, the capacities most closely associated with the creative and analytical breakthroughs this series has repeatedly examined in relation to historical genius. Some studies in this literature have additionally found that stimulants can paradoxically impair performance on certain complex cognitive tasks in individuals who already have high baseline working memory capacity, a finding sometimes explained by an “inverted-U” model of dopaminergic function, in which cognitive performance is optimized at a moderate level of dopaminergic stimulation and can be actively degraded by pushing dopaminergic activity beyond that optimal point in someone whose baseline dopamine function is already well-calibrated for the task at hand.
The Placebo and Motivation Confound
A separate and methodologically important complication in interpreting self-reported benefits of cognitive enhancement substances involves the well-documented and substantial role of expectation and motivation effects. Several controlled studies, including research specifically designed to separate genuine pharmacological effects from placebo and motivational effects, have found that a meaningful portion of users’ subjectively reported cognitive enhancement from stimulant use may reflect increased confidence, motivation, and willingness to persist at tedious or effortful tasks — genuinely useful effects for real-world task completion, but conceptually and mechanistically distinct from a direct pharmacological enhancement of underlying reasoning or creative capacity itself, and a distinction users self-reporting dramatic cognitive benefits are generally poorly positioned to reliably distinguish from the inside.
Genetic Enhancement: CRISPR and the Limits of Polygenic Engineering
The 2012 development of CRISPR-Cas9 gene-editing technology, which earned its developers Jennifer Doudna and Emmanuelle Charpentier the 2020 Nobel Prize in Chemistry, has raised the theoretical possibility of directly editing genes associated with cognitive ability — a possibility that, examined against the genetics research reviewed in this series’ dedicated article on the genetics of genius, faces severe and probably decisive practical obstacles given current and foreseeable technology. As that article discussed in detail, genome-wide association studies have found that cognitive ability and educational attainment are highly polygenic traits, influenced by thousands of individual genetic variants, each contributing an individually vanishingly small effect on the overall trait — a genetic architecture that stands in sharp contrast to the kind of single-gene disorders (such as sickle cell disease or Huntington’s disease) that current CRISPR gene-editing technology is comparatively well-suited to address, where a single, well-identified genetic variant is responsible for the great majority of the associated trait or condition.
Editing thousands of individually near-negligible genetic variants simultaneously, with current gene-editing technology’s still-imperfect precision and with the very substantial risk of unpredictable interactions between edited variants given how little is understood about their combined, non-additive effects, represents a task of an entirely different order of technical difficulty and risk than editing a single well-characterized disease-causing gene — a critical technical distinction that has been noted by numerous geneticists specifically pushing back against sensationalized popular and media coverage suggesting that “designer baby” genetic enhancement for intelligence is a near-term realistic technical possibility. He Jiankui’s widely condemned and scientifically discredited 2018 experiment, in which he used CRISPR to edit the genomes of human embryos (for a different purpose, disease resistance, though the broader controversy is frequently cited in cognitive enhancement discussions), resulted in his imprisonment in China and near-universal condemnation from the international scientific community, and stands as a stark illustration of the current, wide gap between technical capability and both the scientific and ethical maturity required for any form of responsible human genetic engineering, let alone genetic engineering targeting a trait as complex, polygenic, and poorly causally understood at the individual-variant level as cognitive ability.
Embryo Selection: A More Technically Feasible but Ethically Fraught Alternative
A technically distinct and considerably more immediately feasible approach than direct genetic editing involves polygenic embryo screening — using the polygenic risk score methodology discussed in this series’ genetics article, applied not to editing genes directly but to screening and ranking multiple embryos created through in vitro fertilization according to their predicted polygenic score for a given trait, then selecting for implantation the embryo predicted to score most favorably. Several commercial companies have already begun offering forms of polygenic embryo screening for various health-related traits, and cognitive ability polygenic scores could, in principle, be technically incorporated into such screening given the existing extensive GWAS research on educational attainment and cognitive ability.
This approach faces its own serious limitations independent of the ethical debate it has generated: as discussed in this series’ genetics article, current polygenic scores for cognitive ability and educational attainment explain only a modest share of overall trait variance (in the range of 12-16% for educational attainment), meaning that selecting among a realistic small number of available embryos from a single IVF cycle would be expected, based on the modest statistical power current polygenic scores actually provide, to produce only a very small, and for cognitive ability specifically, likely undetectable-in-practice average improvement in a resulting child’s expected cognitive outcomes — a technical limitation that a number of behavioral geneticists, including some who have been broadly supportive of embryo screening for serious monogenic disease risk, have specifically and publicly cautioned against overselling for polygenic, environmentally-interactive traits like cognitive ability specifically, as opposed to more clearly genetically determined single-gene disease conditions where the statistical case for screening’s predictive value is considerably stronger.
The Ethical Debate: Autonomy, Equality, and the “Enhancement Versus Treatment” Distinction
Beyond the purely technical limitations reviewed above, cognitive enhancement research has generated a substantial and active bioethics literature grappling with several distinct ethical concerns that would remain relevant even if the technical obstacles discussed above were eventually overcome. A foundational distinction in this literature, discussed extensively by bioethicists including Norman Daniels and others working in the philosophy of medicine, concerns “treatment versus enhancement” — the proposition that there’s a meaningful ethical distinction between using medical or genetic intervention to restore an individual to a typical, healthy baseline level of functioning (treatment) versus using comparable intervention to push an already typically or healthily functioning individual beyond that baseline (enhancement) — a distinction that shapes much of the ongoing debate about which applications of cognitive-enhancement technology, if any, should be considered ethically acceptable, medically appropriate, or eligible for insurance coverage and mainstream clinical availability, as opposed to which should be restricted, discouraged, or left to individual private choice and expense outside conventional medical practice.
A separate and arguably more socially urgent concern, raised extensively by bioethicists including Michael Sandel in his influential critique of genetic and pharmacological enhancement, concerns distributive justice and equality of access: if effective cognitive enhancement technologies, whether pharmacological or genetic, do eventually become available, there’s a substantial and well-founded concern that access would very likely be stratified by wealth and existing social advantage in a manner that could significantly compound, rather than reduce, already substantial and well-documented existing inequalities in educational and economic opportunity discussed elsewhere in this series — a concern independent of, and arguably more pressing than, the more frequently discussed but more speculative concerns about enhancement’s effects on personal identity, authenticity, and the nature of individually “earned” achievement.
The Current Honest Scientific Position
Synthesizing the technical and ethical threads reviewed in this article, the current, evidence-grounded scientific position on engineering genius is considerably more modest than either enthusiastic popular coverage of gene-editing and nootropic technologies or dystopian science-fiction scenarios of designer superintelligence typically suggest. Available pharmacological cognitive enhancers produce real but modest effects, concentrated in executive function and motivation rather than the fluid reasoning and creative capacity most closely associated with genius-level achievement, and carry documented risks including potential impairment in some already high-functioning individuals. Direct genetic editing for cognitive enhancement faces severe and likely decisive near-term technical obstacles given cognitive ability’s highly polygenic genetic architecture. Embryo selection is more technically feasible but currently offers only a modest expected effect given current polygenic scores’ limited predictive power. And even setting aside these substantial technical limitations, the ethical questions this technology raises regarding equitable access and distributive justice remain, by the assessment of the bioethics literature reviewed here, considerably more difficult to resolve than the underlying scientific and technical challenges themselves.
